Generic drug of Clarityne
Therapeutic class: Allergology
active ingredients: Loratadine
laboratory: Sanofi-Aventis France
Box of 7
DOLIALLERGIE LORATADINE 10 mg tablet is indicated for the symptomatic treatment of allergic rhinitis.
Dosage DOLIALLERGIE LORATADINE 10 mg Tablet Box of 7
Adults and children over 12 years old: 10 mg once a day, one tablet once a day.
The tablet can be taken indifferently with respect to meals.
Children with body weight over 30 kg:
10 mg once a day or a tablet once a day.
The 10 mg tablet form is not suitable for children under 30 kg.
The efficacy and safety of DOLIALLERGIE LORATADINE have not been established in children under 2 years of age.
Severe hepatic insufficiency
In patients with severe hepatic impairment, the initial dose should be decreased due to reduced risk of loratadine clearance. An initial dose of 10 mg every other day is recommended for adults and children over 30 kg.
Elderly or renal failure
No dose adjustment is necessary in elderly or renally impaired patients.
DOLIALLERGIE LORATADINE is contraindicated in case of hypersensitivity to loratadine or to any of the excipients of the drug.
Adverse effects Doliallergie Loratadine
In pediatric clinical studies in children aged 2 to 12 years, the most common adverse events reported with greater frequency than placebo were: headache (2.7%), nervousness (2.3%) and fatigue (1%).
In clinical studies in adults and adolescents in allergic rhinitis and chronic idiopathic urticaria at the recommended dose of 10 mg, adverse events with loratadine were reported in 2% more patients than those treated with placebo. The most frequently reported adverse reactions with greater frequency than placebo were: drowsiness (1.2%), headache (0.6%), increased appetite (0.5%), and insomnia (0.1%). %).
Other side effects reported very rarely since marketing are listed in the following table:
Immune system disorders
Nervous system disorders
Nausea, dry mouth, gastritis
Liver function disorders
Skin and subcutaneous tissue disorders
General disorders and administration site conditions